Table 2 The relationship between DPT expression and clinicopathological characteristics in validated cohort.
From: DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP
Characteristics | Expression of DPT, number (%) | ||
|---|---|---|---|
Low expression (n = 50) (%) | High expression (n = 50) (%) | P-value | |
Age at diagnosis, y | |||
Mean ± SD | 61.94 ± 11.83 | 58.78 ± 10.65 | 0.164 |
≤60 y | 22 (44.00) | 29 (58.00) | 0.161 |
>60 y | 28 (56.00) | 21 (42.00) | |
Tumor size in cm | |||
≤2 cm | 14 (28.00) | 24 (48.00) | 0.039* |
>2 cm | 36 (72.00) | 26 (52.00) | |
Lymph node metastasis | 0.779 | ||
≤3 metastatic sites | 43 (81.63) | 42 (78.48) | |
>3 metastatic sites | 7 (16.17) | 8 (19.85) | |
Metastasis | 0.646 | ||
M0 | 48 (96.00) | 47 (94.00) | |
M1 | 2 (4.00) | 3 (6.00) | |
AJCC disease stage | |||
I + II | 40 (80.00) | 39 (78.00) | 0.806 |
III + IV | 10 (20.00) | 11 (22.00) | |
Estrogen receptor status | 0.509 | ||
Positive | 37 (74.00) | 34 (68.00) | |
Negative | 13 (26.00) | 16 (32.00) | |
Progesterone receptor status | 1.000 | ||
Positive | 28 (56.00) | 28 (56.00) | |
Negative | 22 (44.00) | 22 (44.00) | |
HER2 status | 0.790 | ||
Positive | 8 (16.00) | 9 (18.00) | |
Negative | 42 (84.00) | 41 (82.00) | |
